<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>It is increasingly recognized that alterations in non-insulin-mediated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake (NIMGU) play an important pathogenic role in <z:e sem="disease" ids="C0149670" disease_type="Disease or Syndrome" abbrv="">disorders of carbohydrate metabolism</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This study was conducted to determine whether NIMGU is impaired in elderly patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Healthy elderly control subjects (n = 19, age 76 +/- 1 years, BMI 26.8 +/- 1.1 kg/m2) and elderly patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> (n = 19, age 76 +/- 2 years, BMI 27.5 +/- 0.9 kg/m2) underwent a 240-min <z:chebi fb="105" ids="17234">glucose</z:chebi> clamp study </plain></SENT>
<SENT sid="3" pm="."><plain>Octreotide was infused to suppress endogenous insulin release, and tritiated <z:chebi fb="105" ids="17234">glucose</z:chebi> methodology was used to measure <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and disposal rates </plain></SENT>
<SENT sid="4" pm="."><plain>For the first 180 min, <z:chebi fb="105" ids="17234">glucose</z:chebi> was kept at fasting levels </plain></SENT>
<SENT sid="5" pm="."><plain>From 180 to 240 min, <z:chebi fb="105" ids="17234">glucose</z:chebi> was increased to 11 mmol/l </plain></SENT>
<SENT sid="6" pm="."><plain>At fasting <z:chebi fb="105" ids="17234">glucose</z:chebi> levels, <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake was similar in both groups </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:chebi fb="105" ids="17234">glucose</z:chebi> clearance was reduced in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> (control 1.68 +/- 0.05 ml x kg(-1) x min(-1); <z:mp ids='MP_0002055'>diabetes</z:mp> 1.34 +/- 0.07 ml x kg(-1) x min(-1), P &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>During <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo>, <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake was reduced in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> (control 3.16 +/- 0.09 mg x kg(-1) x min(-1); <z:mp ids='MP_0002055'>diabetes</z:mp> 2.57 +/- 0.11 mg x kg(-1) x min(-1), P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>Peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> effectiveness (SG) was less in patients with <z:mp ids='MP_0002055'>diabetes</z:mp> (control 1.28 +/- 0.04 ml x kg(-1) x min(-1); <z:mp ids='MP_0002055'>diabetes</z:mp> 0.94 +/- 0.08 ml x kg(-1) x min(-1), P &lt; 0.0001) </plain></SENT>
<SENT sid="10" pm="."><plain>Hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output and hepatic SG were not different between groups </plain></SENT>
<SENT sid="11" pm="."><plain>We conclude that the effect of <z:chebi fb="105" ids="17234">glucose</z:chebi> on <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake is impaired in elderly patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, a finding that may have therapeutic implications for this patient population </plain></SENT>
</text></document>